Document is current
Any future updates will be listed below
-
Authors
Manafi, Navid
Oncel, Deniz
Verma, Aditya https://orcid.org/0000-0003-3778-8834
Corradetti, Giulia
Kadomoto, Shin
Mahmoudi, Alireza
Alagorie, Ahmed Roshdy
Yadav, Naresh Kumar
Pappuru, Rajeev R.
Tufail, Adnan https://orcid.org/0000-0001-6131-7640
Esmaeilkhanian, Houri
Nittala, Muneeswar G.
Raman, Rajiv https://orcid.org/0000-0001-5842-0233
Sadda, Srinivas https://orcid.org/0000-0002-4939-3306
- License Information
-
More Information
Article History
Received: 8 February 2023
Revised: 17 March 2024
Accepted: 19 April 2024
First Online: 9 May 2024
Competing interests
: NM, DO, AV, AM, ARA, NKY, RRP, AT, HE, MGN, RR: None; GC: Nidek Incorporated (R); SK: Canon (C), Nidek (C); SS: 4DMT (C), Alexion (C), Allergan, Inc. (C), Alnylam Pharmaceuticals (C), Amgen Inc. (C), Apellis Pharmaceuticals, Inc. (C), Astellas (C), Bayer Healthcare Pharmaceuticals (C), Carl Zeiss Meditec (C, R, F), Catalyst Pharmaceuticals Inc. (C), Centervue, Inc. (C), GENENTECH (C), Gyroscope Therapeutics (C), Heidelberg Engineering (C), (R) (F), Iveric Bio (C), Janssen Pharmaceuticals, Inc. (C), Merck & Co., Inc. (C), Nanoscope (C), Nidek Incorporated (R), Novartis Pharma AG (C) (R), Optos, Inc. (C), Oxurion/Thrombogenics (C), Pfizer, Inc. (C), Regeneron Pharmaceuticals, Inc. (C), Samsung Bioepis (C), Topcon Medical Systems Inc. (R), Vertex Pharmaceuticals Incorporated (C). C=Consultant, R=Recipient, F=Financial Support.
